Edgewise Therapeutics, Inc.
$33.97
▲
0.57%
2026-04-21 06:45:00
edgewisetx.com
NMS: EWTX
Explore Edgewise Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3.69 B
Current Price
$33.97
52W High / Low
$35 / $12.15
Stock P/E
—
Book Value
$4.92
Dividend Yield
—
ROCE
-36.44%
ROE
-34.19%
Face Value
—
EPS
$-1.63
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
146
Beta
0.25
Debt / Equity
0.76
Current Ratio
19.85
Quick Ratio
19.85
Forward P/E
-14.03
Price / Sales
—
Enterprise Value
$2.99 B
EV / EBITDA
-15.82
EV / Revenue
—
Rating
Buy
Target Price
$41.08
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | DiaMedica Therapeutics Inc. | $6.56 | — | $369.1 M | — | -61.16% | -67.68% | $10.42 / $3.28 | $1.04 |
| 2. | Arcutis Biotherapeutics, Inc. | $24.47 | — | $3.04 B | — | -4.03% | -9.3% | $31.77 / $12.42 | $1.54 |
| 3. | Anixa Biosciences, Inc. | $3 | — | $100.58 M | — | -82.91% | -68.06% | $5.46 / $2.44 | $0.45 |
| 4. | Cibus, Inc. | $1.56 | — | $118.83 M | — | -23.41% | -2.21% | $4.19 / $1.09 | $0.4 |
| 5. | Agenus Inc. | $4.42 | 1,529.26 | $175.86 M | — | 21.26% | -0.04% | $7.34 / $1.6 | $-7.68 |
| 6. | Calidi Biotherapeutics, Inc. | $0.25 | — | $3 M | — | -410.2% | -7.01% | $19.2 / $0.21 | $0.51 |
| 7. | Ocugen, Inc. | $1.85 | — | $606.61 M | — | -307.31% | -7.77% | $2.73 / $0.64 | $-0.04 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -55.98 M | -46.86 M | -42.61 M | -45.96 M | -45.54 M | — |
| Net Profit | -50.22 M | -40.67 M | -36.12 M | -40.8 M | -39.66 M | — |
| EPS in Rs | -0.47 | -0.38 | -0.34 | -0.38 | -0.37 | -0.36 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -191.41 M | -158.83 M | -114.36 M | -71.66 M |
| Net Profit | -167.79 M | -133.81 M | -100.16 M | -67.64 M |
| EPS in Rs | -1.56 | -1.25 | -0.93 | -0.63 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 552.6 M | 486.82 M | 340.04 M | 367.1 M |
| Total Liabilities | 30.35 M | 27.6 M | 21.2 M | 20.39 M |
| Equity | 522.26 M | 459.22 M | 318.83 M | 346.72 M |
| Current Assets | 543.38 M | 475.48 M | 327 M | 357 M |
| Current Liabilities | 27.37 M | 23.86 M | 16.77 M | 16.59 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -143.82 M | -109.03 M | -91.95 M | -52.63 M |
| Investing CF | -32.79 M | -184.66 M | 102.89 M | -70.58 M |
| Financing CF | 196.09 M | 249.25 M | 53.17 M | 129.64 M |
| Free CF | -144.07 M | -110.34 M | -97.69 M | -58.18 M |
| Capex | -0.26 M | -1.31 M | -5.75 M | -5.55 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -33.6% | -48.08% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.